Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance

ABSTRACT The Antibody Mediated Prevention (AMP) trials showed that passively infused VRC01, a broadly neutralizing antibody (bNAb) targeting the CD4 binding site (CD4bs) on the HIV-1 envelope protein (Env), protected against neutralization-sensitive viruses. We identified six individuals from the VR...

Full description

Bibliographic Details

Published in:	Journal of Virology
Main Authors:	Paula Cohen, Bronwen E. Lambson, Nonhlanhla N. Mkhize, Chivonne Moodley, Anna E. J. Yssel, Thandeka Moyo-Gwete, Talita York, Asanda Gwashu-Nyangiwe, Nonkululeko Ndabambi, Ruwayhida Thebus, Michal Juraska, Allan C. deCamp, Brian D. Williamson, Craig A. Magaret, Peter B. Gilbert, Dylan Westfall, Wenjie Deng, James I. Mullins, Lynn Morris, Carolyn Williamson, Penny L. Moore
Format:	Article
Language:	English
Published:	American Society for Microbiology 2025-02-01
Subjects:	HIV-1 broadly neutralizing antibodies VRC01 escape acquisition bottleneck
Online Access:	https://journals.asm.org/doi/10.1128/jvi.01730-24